Jim Glasheen

Bio

Jim has been with Technology Partners since 2002. Jim leads the firm's efforts in Consumer Medicine, investing in both medical device and biopharmaceutical companies. Previously, Jim was Managing Director at CIT Venture Capital, leading the Group's effort in Life Science investing. Also, Jim was a leader within McKinsey & Company's Pharmaceutical and Medical Products Practice. Jim earned a B.S. from Duke University and a M.A. and a Ph.D. from Harvard University in Biology. He was a Deutsche Akademische Austauschdienst (DAAD) fellow at Universitaet des Saarlandes, Germany and a post-doctoral fellow at University of California, Berkeley. Jim has published several research papers and had his research highlighted in major media outlets, including: Nature, The New York Times, Scientific American, and CNN. He serves on the boards of ElCelyx, Essentialis, Incline Therapeutics, Medley Health, Revance Therapeutics, Transcend Medical, and TRIA Beauty while also having led Technology Partner's investment in two companies that have since gone public; Iomai (IOMI) and Cadence Pharmaceuticals (CADX). Jim is also an advisor to the Lester Center at University of California, Berkeley and the National Science Foundation (NSF) in Washington, DC.